Filing Flows › Companies › Evommune › Cash flow
Evommune cash flow, quarter by quarter
Latest: Q2 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$20.5M in Q2 2026 · −$74.7M over twelve months
Analysis
In Q2 2026, Evommune generated −$20.3M of operating cash flow and spent $183K on capital projects, leaving free cash flow of −$20.5M. That is $5.7M more than in Q2 2025 (−$26.2M).
Over the twelve months to Jun 30, 2026, operating cash flow was −$74.2M; the largest uses were other investing ($200M), operating cash flow ($74.2M), capital spending ($501K); besides operations, cash came from other financing ($274M), shares issued ($732K); the cash balance fell by $808K.
Operating cash flow was −$20.3M against net income of −$32.2M. The largest differences: accrued liabilities +$6.0M, stock-based pay +$4.6M, payables +$983K.
Free cash flow
Cash runway and the debt wall
Evommune is burning cash: its operations consume cash, a free cash flow of −$74.7M a year at the current rate against $201M of cash and investments: a runway of about 2.7 years before any new financing.
Where the cash came from and went
From profit to cash
Every quarter
| Quarter | Operating cash flow | Capital spending | Net borrowing (+) / repaid (−) | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|---|---|
| Q2 2026 | −$20.3M | −$183K | −$142K | $732K | −$11.5M | −$20.5M |
| Q1 2026 | −$27.5M | −$83K | −$87K | — | −$4.2M | −$27.6M |
| Q4 2025 | −$16.7M | −$104K | −$86K | — | −$17.2M | −$16.8M |
| Q3 2025 | −$9.6M | −$131K | −$95K | — | $33.8M | −$9.8M |
| Q2 2025 | −$26.2M | — | −$96K | $4K | −$56.1M | −$26.2M |
| Q1 2025 | −$23.9M | — | −$96K | $2K | $10.6M | −$23.9M |
| Q4 2024 | −$18.5M | — | −$84K | $11K | $1.9M | −$18.5M |
Evommune: income statement and cash flow
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%. The chart follows the revenue to costs, profit and cash.
Evommune: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.